UBS AM’s AN2 Therapeutics ANTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$942 Buy
+177
New +$937 ﹤0.01% 4132
2024
Q2
– Sell
-76,200
Closed -$248K – 2802
2024
Q1
$248K Buy
+76,200
New +$829K ﹤0.01% 2433

Other funds holding ANTX

UBS AM's ANTX Position: Q3 2026 in Review

UBS AM opened a new position in AN2 Therapeutics (ANTX) in Q3 2026: 177 shares worth $942. The stake represents ﹤0.01% of the portfolio and ranks #4132 among its holdings. This is a return to the name: UBS AM previously reported a position in ANTX as recently as Q1 2024.

UBS AM first reported a position in ANTX in Q1 2024 and has held it in 2 quarters since. The position peaked at $248K in Q1 2024. 67 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

  • UBS AM held 177 shares of AN2 Therapeutics worth $942 as of Q3 2026.
  • AN2 Therapeutics was a new UBS AM position in Q3 2026.
  • AN2 Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4132 holding.
  • UBS AM first reported a position in AN2 Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • UBS AM's AN2 Therapeutics position peaked at $248K in Q1 2024.
  • 67 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.